{"id":5664,"date":"2024-02-21T10:14:29","date_gmt":"2024-02-21T16:14:29","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5664"},"modified":"2025-06-27T11:21:06","modified_gmt":"2025-06-27T16:21:06","slug":"nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/","title":{"rendered":"Nanoscope Therapeutics anuncia su participaci\u00f3n en pr\u00f3ximas conferencias"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p id=\"temp_ReleaseStart\"><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">21 de febrero de 2024<\/span><\/span>\u00a0\/PRNewswire\/ \u2014\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4096602-1&h=2098688343&u=https%3A%2F%2Fnanostherapeutics.com%2F&a=Nanoscope+Therapeutics+Inc.\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en fase avanzada que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraciones maculares relacionadas con la edad (DMAE), anunci\u00f3 hoy que\u00a0<span class=\"xn-person\">Sulagna Bhattacharya<\/span>, director ejecutivo de Nanoscope Therapeutics y otros miembros de su equipo directivo superior participar\u00e1n en dos pr\u00f3ximas conferencias. Los detalles son los siguientes:<\/p>\n<p class=\"prntal\"><b><a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4096602-1&h=2754039870&u=https%3A%2F%2Fbcic.bio.org%2Fabout&a=BIO+CEO+%26+Investor+Conference\" target=\"_blank\" rel=\"nofollow noopener\"><span class=\"xn-person\">CEO de BIO<\/span>\u00a0Conferencia para inversores<\/a><\/b><\/p>\n<p class=\"prntal\"><b>Fecha de la sesi\u00f3n:\u00a0<\/b>lunes, 26 de febrero de 2024<b><br class=\"dnr\" \/>Tiempo de sesi\u00f3n:\u00a0<\/b>4:45 \u2013\u00a0<span class=\"xn-chron\">4:58 p. m. hora del este<\/span><b><br class=\"dnr\" \/>Ubicaci\u00f3n:\u00a0<\/b>Nueva York Marriott Marquis<br class=\"dnr\" \/><b>Presentador:\u00a0<\/b>Sulagna Bhattacharya, directora ejecutiva<\/p>\n<p class=\"prntal\">La Sra. Bhattacharya actualmente forma parte del consejo de administraci\u00f3n de BIO. En su presentaci\u00f3n, ofrecer\u00e1 una visi\u00f3n general de la plataforma de opsinas multicaracter\u00edsticas de Nanoscope y destacar\u00e1 el enfoque independiente del gen que adopta la empresa. Los directivos de Nanoscope tambi\u00e9n estar\u00e1n disponibles para reuniones durante la conferencia.<\/p>\n<p class=\"prntal\"><b>Conferencia privada emergente de biotecnolog\u00eda Evercore ISI 2024<\/b><\/p>\n<p class=\"prntal\"><b>Fecha de la sesi\u00f3n:<\/b>\u00a0mi\u00e9rcoles, 28 de febrero de 2024<b><br class=\"dnr\" \/>Tiempo de sesi\u00f3n:\u00a0<\/b>1:40 \u2013\u00a0<span class=\"xn-chron\">2:10 p.m. hora del este<\/span><b><br class=\"dnr\" \/>Presentador:\u00a0<\/b><span class=\"xn-person\">Sulagna Bhattacharya<\/span>, Director ejecutivo<\/p>\n<p class=\"prntal\">En la charla informal, la Sra. Bhattacharya hablar\u00e1 sobre la plataforma de opsinas multicaracter\u00edsticas de Nanoscope, as\u00ed como sobre los datos cl\u00ednicos recientes de los ensayos cl\u00ednicos en pacientes con retinosis pigmentaria avanzada y enfermedad de Stargardt. Los directivos de Nanoscope tambi\u00e9n estar\u00e1n disponibles para reuniones individuales durante toda la conferencia.<\/p>\n<p class=\"prntal\"><b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas independientes del gen que restauran la visi\u00f3n para millones de pacientes ciegos por enfermedades retinianas hereditarias para las que no existe cura. El principal f\u00e1rmaco de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados preliminares de la fase RESTORE.\u00a0<span class=\"xn-money\">2b<\/span>\u00a0ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para la retinitis pigmentosa (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4096602-1&h=2488427018&u=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04945772%3Fterm%3DNanoscope%26draw%3D2&a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4096602-1&h=3396697306&u=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05417126%3Fterm%3Dnanoscope%26draw%3D2%26rank%3D3&a=NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>DALLAS,\u00a0Feb. 21, 2024\u00a0\/PRNewswire\/ \u2014\u00a0Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that\u00a0Sulagna Bhattacharya, Chief Executive Officer of Nanoscope Therapeutics, and other members of its senior management team will participate in two upcoming conferences. Details are as follows: BIO CEO\u00a0&#038; Investor Conference [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5666,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5664","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces Participation in Upcoming Conferences - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Participation in Upcoming Conferences - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-21T16:14:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:21:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BIOCEO_2024.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/21\\\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/21\\\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Participation in Upcoming Conferences\",\"datePublished\":\"2024-02-21T16:14:29+00:00\",\"dateModified\":\"2025-06-27T16:21:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/21\\\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\\\/\"},\"wordCount\":311,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/21\\\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_BIOCEO_2024.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/21\\\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/21\\\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\\\/\",\"name\":\"Nanoscope Therapeutics Announces Participation in Upcoming Conferences - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/21\\\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/21\\\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_BIOCEO_2024.jpg\",\"datePublished\":\"2024-02-21T16:14:29+00:00\",\"dateModified\":\"2025-06-27T16:21:06+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/21\\\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/21\\\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/21\\\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_BIOCEO_2024.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/NSCOPE_LI_BIOCEO_2024.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/02\\\/21\\\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Participation in Upcoming Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia su participaci\u00f3n en pr\u00f3ximas conferencias - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Participation in Upcoming Conferences - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-02-21T16:14:29+00:00","article_modified_time":"2025-06-27T16:21:06+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BIOCEO_2024.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Participation in Upcoming Conferences","datePublished":"2024-02-21T16:14:29+00:00","dateModified":"2025-06-27T16:21:06+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/"},"wordCount":311,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BIOCEO_2024.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/","url":"https:\/\/nanostherapeutics.com\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/","name":"Nanoscope Therapeutics anuncia su participaci\u00f3n en pr\u00f3ximas conferencias - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BIOCEO_2024.jpg","datePublished":"2024-02-21T16:14:29+00:00","dateModified":"2025-06-27T16:21:06+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BIOCEO_2024.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/02\/NSCOPE_LI_BIOCEO_2024.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/02\/21\/nanoscope-therapeutics-announces-participation-in-upcoming-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Participation in Upcoming Conferences"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5664"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5664\/revisions"}],"predecessor-version":[{"id":9052,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5664\/revisions\/9052"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5666"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5664"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5664"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}